Detalles de la búsqueda
1.
Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation.
J Hepatol
; 2024 May 29.
Artículo
Inglés
| MEDLINE | ID: mdl-38821360
2.
Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients.
Clin Gastroenterol Hepatol
; 21(2): 538-540.e4, 2023 02.
Artículo
Inglés
| MEDLINE | ID: mdl-35123081
3.
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Clin Gastroenterol Hepatol
; 21(6): 1552-1560.e2, 2023 06.
Artículo
Inglés
| MEDLINE | ID: mdl-35934287
4.
Use and outcomes of hepatitis B virus-positive grafts in orthotopic liver transplantation in the United States from 1999 to 2021.
Liver Transpl
; 29(1): 80-90, 2023 01 01.
Artículo
Inglés
| MEDLINE | ID: mdl-35844046
5.
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation.
Epidemiology
; 34(3): 365-375, 2023 05 01.
Artículo
Inglés
| MEDLINE | ID: mdl-36719738
6.
Factors Associated With Readmission in the United States Following Hospitalization With Coronavirus Disease 2019.
Clin Infect Dis
; 74(10): 1713-1721, 2022 05 30.
Artículo
Inglés
| MEDLINE | ID: mdl-34015106
7.
A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis.
Am J Gastroenterol
; 117(11): 1805-1815, 2022 11 01.
Artículo
Inglés
| MEDLINE | ID: mdl-36327436
8.
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Hepatology
; 74(2): 656-666, 2021 08.
Artículo
Inglés
| MEDLINE | ID: mdl-33706421
9.
Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States.
Clin Infect Dis
; 72(10): e558-e565, 2021 05 18.
Artículo
Inglés
| MEDLINE | ID: mdl-32856034
10.
Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C.
J Med Virol
; 93(11): 6257-6266, 2021 11.
Artículo
Inglés
| MEDLINE | ID: mdl-34219250
11.
Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West.
Hepatology
; 71(6): 1910-1922, 2020 06.
Artículo
Inglés
| MEDLINE | ID: mdl-31610027
12.
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
J Hepatol
; 73(3): 540-548, 2020 09.
Artículo
Inglés
| MEDLINE | ID: mdl-32243960
13.
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med
; 376(22): 2134-2146, 2017 06 01.
Artículo
Inglés
| MEDLINE | ID: mdl-28564569
14.
Increased Frequency of Heterozygous Alpha-1-Antitrypsin Deficiency in Liver Explants From Nonalcoholic Steatohepatitis Patients.
Liver Transpl
; 26(1): 17-24, 2020 01.
Artículo
Inglés
| MEDLINE | ID: mdl-31597010
15.
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Hepatology
; 70(3): 788-801, 2019 09.
Artículo
Inglés
| MEDLINE | ID: mdl-30661255
16.
Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment: Observational Pilot Study.
J Med Internet Res
; 22(2): e15532, 2020 02 24.
Artículo
Inglés
| MEDLINE | ID: mdl-32352385
17.
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
J Hepatol
; 70(3): 483-493, 2019 03.
Artículo
Inglés
| MEDLINE | ID: mdl-30414864
18.
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Clin Gastroenterol Hepatol
; 16(11): 1811-1819.e4, 2018 11.
Artículo
Inglés
| MEDLINE | ID: mdl-29306043
19.
Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial.
Liver Transpl
; 24(3): 380-393, 2018 03.
Artículo
Inglés
| MEDLINE | ID: mdl-29171941
20.
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Hepatology
; 66(2): 389-397, 2017 08.
Artículo
Inglés
| MEDLINE | ID: mdl-28128852